Particle Therapy Market-By Type (Proton, Heavy Ion), By Product (Synchrotrons, Cyclotrons), By Services, By System (Multi-Room Systems, Single-Room Systems), By Cancer Type (Pediatric Cancer, Lung Cancer, Bladder, Breast Cancer) & Forecast, 2023-2032

Description

List of Tables

Global Particle Therapy Market will witness over 8.7% CAGR between 2023 and 2032. The market is expected to flourish due to the increasing adoption of cutting-edge particle therapy equipment by leading hospitals and health facilities. For instance, in September 2023, ION Beam Applications S.A. (IBA), a global frontrunner in particle accelerator technology and the foremost provider of proton therapy solutions for cancer treatment, officially inked the conclusive agreement with Medtechnica Ltd. This agreement paves the way for the installation of two state-of-the-art Proteus®ONE compact proton therapy systems at the Sourasky Medical Center, also known as Ichilov Hospital, in Tel Aviv, Israel.

These hospitals are choosing high-quality equipment from top manufacturers, which, in turn, fuels the particle therapy market growth. The precise and effective treatment capabilities of particle therapy are a key factor in this trend, as healthcare providers seek to offer the best possible care to their patients.

The overall Particle Therapy Market is classified based on product, cancer type, and region.

Cyclotrons segment will undergo significant development from 2023 to 2032. Cyclotrons play a pivotal role in cancer treatment by accelerating these particles to precise energies for effective therapies. As the medical community increasingly recognizes the precision and benefits of particle therapy, the demand for cyclotrons is on the rise, supporting the particle therapy market outlook. The demand for cyclotrons, which are integral in producing the necessary particles for proton and heavy ion therapy, is registering high growth due to the above-stated reasons.

The pediatric cancer segment will register a notable CAGR from 2023 to 2032. Particle therapy, including proton and heavy ion therapy, is gaining prominence for its precision and reduced side effects, making it an ideal choice for young cancer patients. As awareness grows about the advantages of particle therapy in treating pediatric cancers, the particle therapy market demand in this specialized field is on the rise.

Asia Pacific particle therapy market will showcase an appreciable CAGR from 2023 to 2032. Factors such as a growing population, increasing cancer incidence, and a greater awareness of the benefits of particle therapy are driving this demand. Asian countries are expanding their healthcare infrastructure to include proton and heavy ion therapy facilities, indicating a significant market growth trajectory in the Asia Pacific. For instance, in October 2023, in a joint statement, Hitachi, Ltd. and Hitachi Asia Ltd. disclosed the successful delivery of a proton therapy system to the National Cancer Centre Singapore ("NCCS"). This achievement marks a groundbreaking moment as Hitachi's inaugural proton therapy system to be operational for patient treatment in Southeast Asia.

Product Code: 6604

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Particle therapy industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Type trends
- 2.1.4 Product & services trends
- 2.1.5 System trends
- 2.1.6 Cancer type trends

Chapter 3 Particle Therapy Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing global burden of cancer
  - 3.2.1.2 Advantages offered by particle therapy
  - 3.2.1.3 Increasing number of particle therapy centers worldwide
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Infrastructural challenges in healthcare facilities
  - 3.2.2.2 Unfavorable reimbursement policies and limited insurance coverage
3.3 Growth potential analysis
- 3.3.1 By type
- 3.3.2 By product & services
- 3.3.3 By system
- 3.3.4 By cancer type
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategy dashboard, 2022

Chapter 5 Particle Therapy Market, By Type, 2018 - 2032 (USD Million)

5.1 Key trends, by type
5.2 Proton therapy
5.3 Heavy ion therapy

Chapter 6 Particle Therapy Market, By Product & Services, 2018 - 2032 (USD Million)

6.1 Key trends, by product & services
6.2 Product
- 6.2.1 Synchrotrons
- 6.2.2 Cyclotrons
- 6.2.3 Synchrocyclotrons
6.3 Services

Chapter 7 Particle Therapy Market, By System, 2018 - 2032 (USD Million)

7.1 Key trends, by system
7.2 Multi-room systems
7.3 Single-room systems

Chapter 8 Particle Therapy Market, By Cancer Type, 2018 - 2032 (USD Million)

8.1 Key trends, by cancer type
8.2 Pediatric cancer
8.3 Lung cancer
8.4 Bladder cancer
8.5 Brain & spinal cord cancer
8.6 Head & neck cancer
8.7 Breast cancer
8.8 Gastrointestinal cancer
8.9 Other cancers

Chapter 9 Particle Therapy Market, By Region, 2018 - 2032 (USD Million)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East & Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

10.1 Danfysik A/S
10.2 Hitachi, Ltd.
10.3 IBA
10.4 Mevion Medical Systems
10.5 Optivus Proton Therapy, Inc.
10.6 ProTom International
10.7 Provision Healthcare
10.8 Sumitomo Heavy Industries, Ltd.
10.9 Siemens Healthcare GmbH
10.10 Advanced Oncotherapy Plc.